02315 百奧賽圖-B
公司資料 - 股權變動
日期 股東名稱 披露原因 買入/賣出涉及
的股份數目
每股平均價 持有權益的
股份數目
佔已發行
股本(%)
07/05/2026富国基金管理有限公司1001(L)+63,500(L)HKD 49.636(L)5,545,000(L)5.01
09/04/2026GIC (Ventures) Pte. Ltd.1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026BioVeda China Fund II RMB, Limited1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026BVCF Realization Fund, L.P.1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026楊志1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026GIC Special Investments Private Limited1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026BVCF Realization Fund GP, Ltd.1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026InnoVeda Medtech, Ltd.1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026GIC Private Limited1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
09/04/2026Prowell Ventures Pte Ltd1313(L)
14012(S)
4,000,000(L)
+4,000,000(S)
14,325,400(L)
4,000,000(S)
12.93
3.61
10/03/2026BVCF Realization Fund GP, Ltd.1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026BVCF Realization Fund, L.P.1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026InnoVeda Medtech, Ltd.1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026BioVeda China Fund II RMB, Limited1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026楊志1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026GIC Private Limited1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026GIC Special Investments Private Limited1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026GIC (Ventures) Pte. Ltd.1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
10/03/2026Prowell Ventures Pte Ltd1201(L)-134,000(L)HKD 61.160(L)14,325,400(L)12.93
11/02/2026维科(香港)经贸有限公司1201(L)-2,605,000(L)HKD 39.797(L)6,283,580(L)5.67
10/02/2026BVCF Realization Fund, L.P.1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026GIC Private Limited1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026InnoVeda Medtech, Ltd.1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026BioVeda China Fund II RMB, Limited1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026GIC Special Investments Private Limited1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026GIC (Ventures) Pte. Ltd.1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026Prowell Ventures Pte Ltd1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026楊志1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
10/02/2026BVCF Realization Fund GP, Ltd.1201(L)-361,500(L)HKD 50.671(L)15,468,900(L)13.96
02/02/2026维科(香港)经贸有限公司1101(L)+786,000(L)HKD 27.278(L)8,888,580(L)8.02
20/01/2026招銀國際金融有限公司1201(L)-1,162,000(L)16,549,544(L)14.94
20/01/2026招銀國際金融控股有限公司1201(L)-1,142,500(L)16,569,044(L)14.96
20/01/2026CMB International Private Investment Limited1201(L)-1,142,500(L)16,569,044(L)14.96
20/01/2026招銀國際金融控股有限公司1201(L)-1,162,000(L)16,549,544(L)14.94
20/01/2026Astral Eminent Limited1201(L)-1,142,500(L)16,569,044(L)14.96
20/01/2026CMBI Private Equity Series SPC1201(L)-1,142,500(L)16,569,044(L)14.96
20/01/2026CMBI Private Equity Series SPC1201(L)-1,162,000(L)16,549,544(L)14.94
20/01/2026CMB International Private Investment Limited1201(L)-1,162,000(L)16,549,544(L)14.94
20/01/2026招銀國際金融有限公司1201(L)-1,142,500(L)16,569,044(L)14.96
20/01/2026招商銀行股份有限公司1201(L)-1,162,000(L)16,549,544(L)14.94
 1    2    3    4  
備註: (L) - 長倉:包括 (1) 持有股份;(2) 透過持有、沽出或發行金融合約,有權或有責任購買相關股份。
  (S) - 短倉:包括 (1) 借入股份;(2) 透過持有、沽出或發行金融合約,有權或有責任沽出相關股份。
  (P) - 可供借出的股份
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.